Effects of sarizotan in animal models of ADHD: challenging pharmacokinetic-pharmacodynamic relationships

Journal of Neural Transmission
Wojciech DanyszChristopher G Parsons

Abstract

Sarizotan 1-[(2R)-3,4-dihydro-2H-chromen-2-yl]-N-[[5-(4-fluorophenyl) pyridin-3-yl]methyl] methenamine, showed an in vivo pharmaco-EEG profile resembling that of methylphenidate which is used in attention deficit/hyperactivity disorder (ADHD). In turn, we tested sarizotan against impulsivity in juvenile rats measuring the choice for large delayed vs. a small immediate reward in a T-maze and obtained encouraging results starting at 0.03 mg/kg (plasma levels of ~11 nM). Results from rats treated neonatally with 6-hydroxydopamine (6-OHDA), also supported anti-ADHD activity although starting at 0.3 mg/kg. However, microdialysis studies revealed that free brain concentration of sarizotan at active doses were below its affinity for 5-HT1A receptors, the assumed primary target. In contrast, electrophysiological experiments in mid-brain Raphé serotonergic cells paralleled by plasma sampling showed that there was ~60% inhibition of firing rate—indicating significant activation of 5-HT1A receptors—at a plasma concentration of 76 nM. In line with this, we observed that sarizotan concentrations in brain homogenates were similar to total blood levels but over 500 fold higher than free extracellular fluid (ECF) concentrations as measured usi...Continue Reading

References

Jul 1, 1991·Pharmacology, Biochemistry, and Behavior·R M Kostrzewa, L Gong
Oct 1, 1986·Physiology & Behavior·J P Kroon, A L Riley
Jan 1, 1994·Brain Research Bulletin·R M KostrzewaR W Fuller
Feb 10, 2004·Journal of Neural Transmission·G D BartoszykC A Seyfried
Jul 13, 2005·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·Wilfried Dimpfel
Sep 2, 2006·Naunyn-Schmiedeberg's Archives of Pharmacology·Marie-Bernadette AssiéAdrian Newman-Tancredi
Nov 10, 2006·Movement Disorders : Official Journal of the Movement Disorder Society·Christopher G GoetzHermann Russ
Jan 5, 2007·Journal of Child and Adolescent Psychopharmacology·John S MarkowitzRafael Muniz
Feb 6, 2007·Journal of Neuroscience Methods·Vivienne Ann Russell
Feb 13, 2007·Neurobiology of Disease·Xueliang Fan, Ellen J Hess
Jun 5, 2007·International Journal of Clinical Pharmacology and Therapeutics·S KrösserA Kovar
Nov 13, 2007·Journal of Neural Transmission·R M KostrzewaR Brus
Jan 5, 2008·Movement Disorders : Official Journal of the Movement Disorder Society·Christopher G GoetzHermann Russ
Feb 29, 2008·Trends in Pharmacological Sciences·Tommy Pattij, Louk J M J Vanderschuren
Jul 23, 2008·European Journal of Paediatric Neurology : EJPN : Official Journal of the European Paediatric Neurology Society·Paolo CuratoloAugusto Pasini
Sep 6, 2008·Progress in Brain Research·Robert D Oades
Jul 25, 2009·Neuropharmacology·Gail Tripp, Jeffery R Wickens
Oct 30, 2012·Attention Deficit and Hyperactivity Disorders·Terje TorgersenHans M Nordahl
Jan 12, 2013·Genetic Testing and Molecular Biomarkers·Young Hyun ParkMyung Ho Lim

❮ Previous
Next ❯

Related Concepts

Related Feeds

Attention Disorders

Attention is involved in all cognitive activities, and attention disorders are reported in patients with various neurological diseases. Here are the latest discoveries pertaining to attention disorders.

© 2021 Meta ULC. All rights reserved